Search PubMed⌕ Search

Biomedical subjects

H J Lerner

Publications and source records attributed to H J Lerner.

At least 37 records · Page 2Linked to original sources
PubMed1977

Concomitant hydroxyurea and irradiation. Clinical experience with 100 patients with advanced head and neck cancer at Pennsylvania hospital.

One hundred outpatients with proved advanced epidermoid carcinoma of the head and neck underwent complete treatment with concomitant hydroxyurea and irradiation therapy. Seventy-three patients exhibited complete regression of the tumor. All patients became candidates for operation after completion of combination therapy, although not all patients accepted surgery.

Carcinoma, Squamous Cell↗
PubMed1977

Hydroxyurea in stage D carcinoma of prostate.

Thirty patients with histologically proved metastatic prostatic adenocarcinoma Stage D were treated with a single oral dose of 80 mg. per Kg. hydroxyurea every third day (based on ideal or actual weight, whichever is less) and 12 mg. chlorotrianisene per day. Toxicity was mild. The most common manifestations were nausea, occasional vomiting, and leukopenia. A definite attempt was made to depress the white blood count to approximately 2,000 cells per cu. mm. Hydroxyurea was not discontinued unless the white blood count decreased to less than 2,000 cells per cu. mm., after which a single dose was usually omitted. Omission of a single dose would allow the white blood count to return promptly to more than 2,000 cells per cu. mm. Objective tumor regression was demonstrated in 15 of the 30 patients, and most patients had a definite improvement in the quality of life.

Aged↗
PubMed1976

Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer.

Tamoxifen (NSC-180973), a synthetic antiestrogen, was studied for efficacy and toxicity in patients with metastatic breast adenocarcinoma. Two dose levels were used, 10 mg bid and 15 mg/m2 bid, in separate groups. In the 10-mg bid dosage group, 30 of the 31 patients were considered evaluable for efficacy. Five complete and 11 partial responses were recorded, for an overall response rate of 53%. In the 15-mg/m2 bid dosage group, 44 of the 45 patients were considered evaluable for efficacy. Three complete and 16 partial responses were recorded, for an overall response rate of 43%. All 76 patients were evaluated for toxicity. Side effects were generally mild, consisting mostly of hot flushes, transient leukopenia, transient thrombocytopenia, nausea, and fluid retention. A high degree of correlation between response and positive estrogen-receptor assay suggests the value of the test as a means to select patients for tamoxifen treatment. The conclusion from this study is that tamoxifen used as a single agent is an effective drug with minimal toxicity for treatment of metastatic breast adenocarcinoma.

Adenocarcinoma↗
PubMed1975

Colorectal cancer--prognostic signs in "local disease".

This detailed review of the clincal and pathologic signs which effect the prognosis of patients with colorectal cancer. The following are reviewed: (1) the degree of cellular anaplasia, (2) local penetration of the bowel wall, (3) lymph-node spread, (4) venous invasion, (5) perineural invasion, (6) obstruction and perforation, and (7) the number of cm the lesion is located from the anal verge.

Colon↗